Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Dow, S&P 500 fall, tech steadies to end rocky weekÂ
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude jumps to highest since April on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
| (NASDAQ: KROS) | Delayed: 11.20 -0.15 (1.32%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $11.35 | 52 Week High | $ | |||
| Open | $11.28 | 52 Week Low | $ | |||
| Day High | $11.29 | P/E | N/A | |||
| Day Low | $10.92 | EPS | $ | |||
| Volume | 49,130 | |||||
